Eisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-on

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia rights to its add-on schizophrenia treatment.